0001599298-24-000006.txt : 20240104 0001599298-24-000006.hdr.sgml : 20240104 20240104161645 ACCESSION NUMBER: 0001599298-24-000006 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240102 FILED AS OF DATE: 20240104 DATE AS OF CHANGE: 20240104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DUGGAN ROBERT W CENTRAL INDEX KEY: 0001055919 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 24512130 MAIL ADDRESS: STREET 1: 611 SOUTH FORT HARRISON AVE STREET 2: SUITE 306 CITY: CLEARWATER STATE: FL ZIP: 33756 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 617-514-7149 MAIL ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 4 1 wk-form4_1704402965.xml FORM 4 X0508 4 2024-01-02 0 0001599298 Summit Therapeutics Inc. SMMT 0001055919 DUGGAN ROBERT W C/O SUMMIT THERAPEUTICS INC. 2882 SAND HILL ROAD, SUITE 106 MENLO PARK CA 94025 1 1 1 0 Co-Chief Executive Officer 0 Stock Option (right to buy) 2.64 2024-01-02 4 A 0 74545 1.32 A 2034-01-02 Common Stock 74545 74545 D The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $98,400. /s/ Ankur Dhingra, as Attorney-in-Fact for Robert W. Duggan 2024-01-04